Chronic neutrophilic leukemia interventions: Difference between revisions
Homa Najafi (talk | contribs) |
Homa Najafi (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chronic neutrophilic leukemia}} | {{Chronic neutrophilic leukemia}} | ||
{{CMG}}; | {{CMG}}; {{AE}} {{Homa}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:55, 5 February 2019
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia interventions On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia interventions |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
There are no recommended therapeutic interventions for the management of [disease name].
OR
[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
OR
[Name of intervention] is the mainstay of treatment for [disease or malignancy].
Indications
The mainstay of treatment for TT is medical therapy.
- Hematopoitic stem cell transplant (HSCT): HSCT is the only potential therapeutic option for patients with CNL. It is recommended that every patients that are qualified for HSCT, take this treatment. Since, the therapy in blast phases has the poor outcomes, HSCT should be started as soon as possible in the disease course, before blast transformation.[1][2][3][4]
- Splenic irradiation
References
- ↑ Elliott, M A; Hanson, C A; Dewald, G W; Smoley, S A; Lasho, T L; Tefferi, A (2004). "WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature". Leukemia. 19 (2): 313–317. doi:10.1038/sj.leu.2403562. ISSN 0887-6924.
- ↑ Kako, Shinichi; Kanda, Yoshinobu; Sato, Tomohiko; Goyama, Susumu; Noda, Naohiro; Shoda, Eriko; Oshima, Kumi; Inoue, Morihiro; Izutsu, Koji; Watanabe, Takuro; Motokura, Toru; Chiba, Shigeru; Fukayama, Masashi; Kurokawa, Mineo (2007). "Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation". American Journal of Hematology. 82 (5): 386–390. doi:10.1002/ajh.20805. ISSN 0361-8609.
- ↑ Szuber, Natasha; Tefferi, Ayalew (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer Journal. 8 (2). doi:10.1038/s41408-018-0049-8. ISSN 2044-5385.
- ↑ Cigudosa, Juan C; Menezes, Juliane (2015). "Chronic neutrophilic leukemia: a clinical perspective". OncoTargets and Therapy: 2383. doi:10.2147/OTT.S49688. ISSN 1178-6930.